This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers visit http://www.djreprints.com.
Updated June 17, 2022 3:04 pm ET / Original June 17, 2022 3:00 am ET
- Order Reprints
- Print Article
Illustration by Mark Pernice
When GlaxoSmithKline spins off its enormous division selling drugstore staples like Advil and Tums next month, it will represent more than just the latest shuffling of assets among corporate giants.
It will mark what is effectively the end of GlaxoSmithKline, diversified pharma conglomerate, and the birth of GSK (ticker: GSK), a rebranded pure-play biopharma.